XTalks

MARCH 1, 2021

The study is part of a broad development plan to assess the durability of the immunogenic responses elicited by its vaccine and the emergence of new SARS-CoV-2 variants. The study will be a part of current Phase I, II and III trials. The third booster will be given to participants from the Phase I study in the US.

Vaccination 111

Vaccination Vaccine Development In-Vitro 111

Pharmaceutical Technology

JUNE 6, 2023

According to Globaldata, it is involved in 5 clinical trials, which are ongoing. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). The drug candidate is a marine-derived compound. Buy the model here.

Hormones 100

Hormones In-Vitro Genotype Bacteria 100

Drug Discovery World

MARCH 8, 2024

Biopharmaceutical company Innovent Biologics has launched the first-in-human (FIH) Phase I clinical trial of IBI3002, a novel bispecific antibody targeting Interleukin 4 receptor α (IL-4Rα) and thymic stromal lymphopoietin (TSLP). In vitro assays have shown superiority over the marketed monoclonal antibodies to respective target.

Antibody 52

Antibody Trials In-Vitro Clinical Trials 52

Drug Discovery World

OCTOBER 25, 2023

iOnctura, a clinical-stage biotech developing selective cancer therapies against targets that play critical roles in multiple tumour survival pathways, has published new research data in the peer-reviewed journal Cancer Research, that supports a strategy of combining autotaxin inhibitor IOA-289 with TGF-β pathway inhibitor IOA-359.

Research 52

Research In-Vivo In-Vitro Clinical Development 52

pharmaphorum

OCTOBER 29, 2020

insitro has landed another big biopharma partnership, signing a five-year collaboration with Bristol Myers Sqibb to develop therapies for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). . insitro uses machine-learning technology to discover novel drug targets and patient segments.

Development 44

Development DNA In-Vitro Genome 44

Drug Discovery World

APRIL 25, 2023

University of California researchers have dosed the second participant in their clinical trial to identify a potential cure for HIV utilising CAR-T cell therapy. The trial is the first-in-human clinical study investigating the duo CAR-T cell therapy for the treatment of HIV. In 2021 there were an estimated 1.5

Research 52

Research In-Vitro Clinical Trials Clinical Trials 52

Drug Discovery World

OCTOBER 4, 2022

DDW Editor Reece Armstrong explores some of the trends that will be featured in sessions throughout ELRIG Drug Discovery 2022 and the news behind them. With 3,633 advanced therapeutical medicinal products (ATMPs) currently in some form of clinical or pre- clinical development, the sector shows no signs of slowing down.

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

The Pharma Data

JANUARY 6, 2021

The research collaboration is aimed at identifying novel lead compounds and repurposing existing drugs for rheumatoid arthritis and nonalcoholic steatohepatitis, leveraging Standigm’s AI-powered drug discovery platforms : Standigm BEST , Standigm Insight , and Standigm ASK. Standigm is an AI-driven drug discovery company.

FDA Approval 52

FDA Approval Life Science Drugs In-Vivo 52

pharmaphorum

JULY 6, 2022

The JV has been formed German pharma companies Boehringer Ingelheim and Evotec with in vitro diagnostics specialist bioMérieux, with the objective of developing new antimicrobial drugs backed by diagnostics to quickly identify pathogens and their resistance patterns and guide treatment.

In-Vitro 57

In-Vitro Development Pharma Companies Drugs 57

Drug Discovery World

JULY 3, 2023

Key updates The findings presented by Dr Christian Klein, Head of Oncology Programs and Department Head of Cancer Immunotherapy Discovery, Roche Innovation Center Zurich, Roche Pharma Research & Early Development, pRED, bear major implications for the development of the next-generation of IL-2 therapies.

Antibody 52

Antibody In-Vitro Engineer In-Vivo 52

pharmaphorum

NOVEMBER 9, 2022

for the purpose of advancing disease-modifying oral medicines for debilitating chronic neurodegenerative disorders, by enabling investigational new drugs (IND) studies. A pre-clinical pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability pore (mPTP) are to be developed.

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52

The Pharma Data

JANUARY 12, 2021

Dr Graham is a medicines development expert and Infectious Diseases Epidemiologist with global Biotech and Pharma R&D experience in Phase I-IV therapeutics as well as in-vivo & in-vitro diagnostics, across many modalities. He has in depth Global Development Expertise (e.g. Dr. Graham earned an M.D.,

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

The Pharma Data

JANUARY 19, 2021

The company hopes to raise $140 million of common stock, which will be used to advance its clinical and earlier stage programs and for R&D, working capital and general corporate purposes. TCR 2 is developing novel T-cell therapies for solid tumors and hematological cancers. With this kind of a start, 2021 may be scorching.

In-Vitro 52

In-Vitro Production Trials Manufacturing 52

The Pharma Data

APRIL 4, 2022

Chief Medical Officer and Head of Global Product Development, Roche. today announced that the U.S. FDA approval is expected in the second half of this year. The sBLA submission is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVID-19 in more than 5,500 hospitalised patients.

FDA Approval 52

FDA Approval Clinical Trials Clinical Trials In-Vitro 52

The Pharma Data

MAY 31, 2022

Food and Drug Administration (FDA) has approved a label extension for Evrysdi® (risdiplam) to include babies under two months old with spinal muscular atrophy (SMA). Roche’s Chief Medical Officer and Head of Global Product Development. Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S.

FDA Approval 52

FDA Approval Protein In-Vitro Medicine 52

Drug Discovery World

MAY 16, 2023

Skills gap Bruce Levine, International Society for Cell & Gene Therapy (ISCT) Immediate Past President and Chair, Strategic Advisory Council, says a critical challenge that has become apparent for the CGT sector is the need for workforce development and training resources. What are the global innovations in cell and gene therapy?

Gene Therapy 52

Gene Therapy Gene Manufacturing Marketing 52

The Pharma Data

DECEMBER 9, 2020

Uniquely positioned in the rapidly evolving local biotech ecosystem in China in addition to an expansive global presence, Overland will strategically partner to jointly develop innovative, novel therapeutics. We look forward to developing and advancing our differentiated pipeline of novel therapeutics in carefully selected disease areas.”.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

The Pharma Data

MARCH 29, 2022

Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months Evusheld retains neutralising activity against the Omicron BA.2 2 subvariant, now the dominant strain in Europe. 1-3 Evusheld was generally well-tolerated in the trial. Christoph D.

Antibody 52

Antibody In-Vivo Vaccination Vaccine 52

The Pharma Data

MAY 27, 2022

Food and Drug Administration (FDA), are planned this year. Glofitamab is being investigated in several clinical trials and explored in earlier lines of lymphoma treatment. The pivotal phase II NP30179 expansion study included patients with heavily pre-treated and highly refractory DLBCL, with 58.3% After a median follow-up of 12.6

Antibody 52

Antibody In-Vitro Medicine Engineer 52

The Pharma Data

MAY 15, 2023

Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Vabysmo® (faricimab) for the treatment of macular edema following retinal vein occlusion (RVO). Roche’s Chief Medical Officer and Head of Global Product Development.

Antibody 40

Antibody In-Vitro Clinical Development Medicine 40

The Pharma Data

OCTOBER 22, 2020

The Company intends to use the net proceeds from this offering to support its planned New Drug Application submission for oral sulopenem for the treatment of uncomplicated urinary tract infections in patients with quinolone-resistant pathogens, the continued clinical development of sulopenem, and for working capital and general corporate purposes.

In-Vitro 40

In-Vitro Clinical Trials Clinical Trials Sales 40

The Pharma Data

NOVEMBER 12, 2021

The upper bound of the 95 CI is within the destined3.5non-inferiority periphery set for the trial’s primary endpoint in discussion with the US Food and Drug Administration (FDA). GlaxoSmithKline plc (LSE/ NYSE GSK) and Vir Biotechnology,Inc. In the IM administration (500 mg) arm of the trial, there was a2.7 George Scangos,Ph.D.,

Trials 40

Trials In-Vitro Antibody Clinical Development 40

Drug Discovery World

DECEMBER 13, 2023

A novel, multi-specific CD73/PD-1 targeting drug-Fc conjugate (DFC) exhibited robust anti-tumour activity in humanised mouse models of colorectal cancer at low doses, according to data presented at the ESMO Immuno-Oncology (IO) Annual Congress. “We

In-Vitro 52

In-Vitro Drugs Antibody Clinical Development 52

The Pharma Data

JUNE 26, 2021

Roche’s Chief Medical Officer and Head of Global Product Development. Roche’s Chief Medical Officer and Head of Global Product Development. Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Roche-sponsored global trials included the placebo-controlled EMPACTA, COVACTA and REMDACTA studies.

Clinical Trials 40

Clinical Trials Clinical Trials In-Vitro Antibody 40

The Pharma Data

APRIL 12, 2023

Chief Medical Officer and Head of Global Product Development. Chief Medical Officer and Head of Global Product Development. Chief Medical Officer and Head of Global Product Development. Chief Medical Officer and Head of Global Product Development. “We

Antibody 40

Antibody In-Vitro Development Trials 40

The Pharma Data

SEPTEMBER 9, 2020

Food and Drug Administration (FDA) for adults with anti-aquaporin-4 (AQP4) antibody positive NMOSD. Roche’s Chief Medical Officer and Head of Global Product Development. “The Roche’s Chief Medical Officer and Head of Global Product Development. Ongoing data continues to show a favourable safety profile for ENSPRYNG.

Antibody 52

Antibody Medicine HR In-Vitro 52

The Pharma Data

SEPTEMBER 19, 2020

Basel, 19 September 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical development programme in triple-negative breast cancer (TNBC) at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

HR 52

HR Medicine In-Vitro Development 52

The Pharma Data

AUGUST 16, 2020

Approval supported by one of the largest clinical trial programmes undertaken for this rare disease. Chief Medical Officer and Head of Global Product Development. “We We thank the NMOSD community, including patients and investigators who participated in ENSPRYNG clinical trials.”. “We

FDA Approval 52

FDA Approval Antibody Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 13, 2020

Selected Clinical Parameters in Patients with Type 2 Diabetes at 12 Weeks. Selected Clinical Parameters in Patients with Type 2 Diabetes at 12 Weeks. PXL770 is a first-in-class, oral direct adenosine monophosphate-activated protein kinase (AMPK) activator.

Trials 52

Trials In-Vitro Insulin Protein 52

Pharmaceutical Technology

AUGUST 26, 2008

The dynamic has now changed as many big companies have now acquired biotechnology companies or have developed ‘biotechnology divisions’ of their own. It was once derided as the stuff of science fiction, but in recent years, biotechnology has emerged as an important growth area in pharmaceuticals.

Antibody 130

Antibody Licensing Licensing Production 130

Drug Discovery World

FEBRUARY 22, 2024

This article is sponsored by Collaborative Drug Discovery. Libra Therapeutics is a San Diego-based biotech focused on developing novel disease-modifying therapeutics, which restore the cellular balance that is disrupted in neurodegenerative diseases. Security built in to CDD Vault is critical when working with multiple CROs.

Clinical Trials 52

Clinical Trials Clinical Trials Trials In-Vivo 52

The Pharma Data

SEPTEMBER 16, 2020

New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Roche’s Chief Medical Officer and Head of Global Product Development. “As New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers.

HR 52

HR Medicine Hormones Trials 52

Drug Discovery World

AUGUST 7, 2023

DDW’s Reece Armstrong speaks to Shantanu Dhamija , VP of Strategy and Innovation at Molecular Devices about challenges of diversity in clinical trials and why induced pluripotent stem cells might be key to representing wider patient groups. RA: Why is US clinical trial diversity at its lowest point in the last 10 years?

Development 98

Development Clinical Trials Clinical Trials Drugs 98

Drug Discovery World

JANUARY 17, 2024

Challenges in the Oncology Clinical Trials Space The oncology market is a key growth driver for the pharma industry, with global drug revenues expected to reach US$390 billion by 2027 and the annual number of new cancer cases set to grow from 18 to 27 million by 2040 1,2.

Medicine 59

Medicine DNA Genome Genomics 59

XTalks

NOVEMBER 15, 2023

France-based biotech Valneva has won approval from the US Food and Drug Administration (FDA) for its chikungunya vaccine Ixchiq for the prevention of infection from the chikungunya virus. The featured speakers will discuss how innovative technologies and automation contribute to advancing vaccine development.

FDA Approval 59

FDA Approval Vaccination Vaccine In-Vitro 59

Drug Discovery World

FEBRUARY 15, 2023

Evolution of such defence mechanisms can lead to multi-drug resistance, further disease progression, and cancer metastasis. Further discovery of PD-1 and CTLA4 as negative immune regulators led to the development of a new class of cancer therapeutics, namely the immune checkpoint inhibitors 5,6.

Research 52

Research In-Vitro In-Vivo Development 52

Drug Discovery World

FEBRUARY 28, 2023

With only 10% of these conditions indicated for an approved therapy, there is a sizable opportunity for scientists and companies to develop treatments for patients with no other options to turn to. Approximately 7,000 rare and ultra-rare diseases have been described, and yet, 90% have no approved therapeutic options 1.

Genetics 52

Genetics Genetic Analysis Vaccination Vaccine 52